Do Alzheimer’s and Lewy body disease have discrete pathological signatures of gait? by Mc Ardle R et al.
Alzheimer’s & Dementia 15 (2019) 1367-1377Theoretical Article
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license (http://creativereflective of underlying pathology by considering two dementia subtypes, Alzheimer’s disease (AD)
and Lewy body disease (LBD), and exploring the role of cognition in disease-specific gait impairments.
Background: Accurately differentiating AD and LBD is important for treatment and disease man-
agement. Early evidence suggests gait could be a marker of dementia due to associations between
discrete gait characteristics and cognitive domains.
Updated Hypothesis: We hypothesize that AD and LBD have unique signatures of gait, reflecting
disease-specific cognitive profiles and underlying pathologies. An exploratory study included indi-
viduals with mild cognitive impairment or dementia due to LBD (n 5 45) and AD (n 5 36) and
29 older adult controls. An instrumented walkway quantified 16 gait characteristics reflecting five in-
dependent domains of locomotion (pace, rhythm, variability, asymmetry, and postural control). The
LBD group demonstrated greater impairments in asymmetry and variability compared with AD; both
groups were more impaired in pace and variability domains than controls. Executive dysfunction ex-
plained 11% of variance for gait variability in LBD, whereas global cognitive impairment explained
13.5% of variance in AD; therefore, gait impairments may reflect disease-specific cognitive profiles.
With a refined hypothesis that AD- and LBD-specific signatures of gait reflect discrete pathologies,
future studies must examine the relationship between a validated model of gait with neural networks,
using recognized biomarkers and postmortem follow-up.
Major Challenges for Hypothesis: Differential diagnosis of AD and LBD used appropriate criteria
and required consensus from an expert diagnostic panel to improve diagnostic accuracy. Future work
should follow the framework set out in Parkinson’s disease to establish unique signatures of gait as
proxy measures of disease-specific pathology; that is, use a validated gait model to explore the pro-
gressive relationship between gait, cognition, and pathology.
Linkage to Other Major Theories: These exploratory findings support the theory of interacting
cognitive-motor networks, as the gait-cognition relationship may reflect cognitive control over motor
networks. Unique signatures of gait may reflect different temporal patterns of pathological burden in
neural areas related to cognitive and motor function.
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The objective of this article is to refine the current
proposal that people with dementia may have a unique
signature of gait impairment reflective of underlyingimer’s Association. This is an open access article under the CC BY-NC-ND
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investigate if gait analysis can distinguish cognitive impair-
ments due to Alzheimer’s disease (AD) and Lewy body dis-
ease (LBD) from each other and controls and if discrete gait
impairments are explained by different cognitive impair-
ments, which reflect AD’s and LBD’s cognitive profiles
and underlying neuropathologies. This effort aims to provide
initial evidence that gait could be a proxy measure for
disease-specific pathology and provide recommendations
for the design of future studies, such as key gait characteris-
tics to assess information required for future power
calculations.2. Introduction
Early accurate diagnosis of dementia is important to
allow individuals to understand their condition, make plans
for their care, and to appropriately manage and treat the dis-
ease [1]. Gait impairments, such as slower pace and greater
gait variability (i.e., step-to-step fluctuations such as changes
in step length or time), occur in prodromal stages of demen-
tia [2] and may predict dementia diagnosis [3]. As gait is a
complex cognitive task requiring coordination between
widespread brain regions [4–6], gait impairments may
reflect neurodegeneration due to dementia even in mild
stages of the disease. Therefore, gait analysis may be a
useful prescreening tool to distinguish mild stages of
dementia from normal aging.
In addition to indicating the presence of dementia, gait
analysis may have potential to distinguish disease sub-
types [7]. This may be useful for differentiating AD and
LBD, which includes dementia with Lewy bodies (DLB)
and Parkinson’s disease dementia (PDD). Due to under-
recognition and inconsistent application of diagnostic
criteria, LBD is underdiagnosed and may be mistaken
for AD [8,9]. Accurate diagnosis is important for
treatment and disease management, as people with LBD
have a high sensitivity to antipsychotics, along with
greater carer burden and frequency of hospital
admission, lower quality of life, faster cognitive decline,
and mortality [10,11].
There is growing evidence of an association between
discrete gait and cognitive impairments [12]. For example,
an individual with executive and attentional dysfunction
may walk slower with greater variability of gait. Different
profiles of cognitive impairment are found in dementia sub-
types in mild disease stages [13], such as prominent memory
impairment in AD, and attentional fluctuations and execu-
tive dysfunction in LBD. These cognitive impairments
may reflect disease pathology in specific neural networks
and regions. Gait impairments can differentiate amnestic
and nonamnestic mild cognitive impairment (MCI) groups
[14]; however, there is limited evidence in clinically defined
AD and LBD groups as most studies only measure gait
speed, which is not specific to subtype, and report inadequate
clinical and cognitive measures [7].3. Updated hypothesis
As such, we hypothesize that AD and LBD have unique
signatures of gait impairment, which reflect their distinct
cognitive profiles and underlying disease pathology. This
refinement of the gait-dementia hypothesis requires further
exploration in AD and LBD cohorts with well-defined gait
and cognitive profiles. Gait impairments should be
compared between older adult controls and aforementioned
disease groups to account for age-related gait impairments,
while examining if the role of cognition in gait may act as
proxy for neuropathology. This research will lay a founda-
tion to consider the association of gait with markers of pa-
thology, such as imaging, cerebrospinal fluid (CSF), and
genetics, and assess the utility of gait analysis as a clinical
tool for dementia diagnosis. We present early evidence for
unique pathological signatures of gait in AD and LBD
from our exploratory study.3.1. Early experimental data—Methods
3.1.1. Participants
Participants with probable MCI and probable dementia
due to AD and LBD (including DLB and PDD) were re-
cruited. Two clinicians (A.T. and P.D.) reviewed patients’
clinical notes and study assessments to verify the diag-
nosis for the study. A third clinician (J.P.T.) reviewed dis-
agreements regarding diagnosis to reach a consensus.
Standard research diagnostic criteria for dementia were
applied [15–20]: Supporting biomarkers were included
in the diagnosis where available. All participants had
mental capacity to consent to the study. Control
participants of a similar age were recruited to account
for effects of aging on gait.
All participants had to be aged over 60 years and be able
towalk for two minutes, as ascertained by self-report. Partic-
ipants were excluded if they had drug-induced or vascular
parkinsonism, any coexisting neurological conditions or
movement disorders, severe mental illness (major depres-
sion, bipolar disorder, schizophrenia), evidence of stroke
affecting motor function, or poor command of the English
language. Controls must have had no signs of cognitive
impairment (Mini–Mental State Examination [MMSE] 
25), be functionally independent, no diagnosis of dementia,
no diagnosis of Parkinson’s disease (PD), and not on treat-
ment for dementia (e.g., memantine, rivastigmine, donepe-
zil, galantamine) or PD medication.
3.1.2. Ethical considerations
The NHS Local Research Ethics Committee, Newcastle
and North Tyneside 1, approved this study, Reference: 16/
NE/005, IRAS project ID: 192941.
3.1.3. Clinical assessment
Age, sex, height, weight, and faller status (if participants
had fallen in the last 12months) were recorded. The National
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Geriatrics, Movement Disorders Society Unified Parkin-
son’s Disease Rating Scale Part III [21], Clinical Dementia
Rating Scale, and Bristol Activities of Daily Living Scale
were also assessed.
3.1.4. Cognitive assessment
Global cognition was measured using the standardized
MMSE and Addenbrooke’s Cognitive Examination III
(ACE-III). The ACE-III subscales measured attention,
memory, language, fluency, and visuospatial function.
Trail Making Task A (TMT-A) measured information pro-
cessing speed. Trail Making Task B (TMT-B) measured
executive function; however, 33% of participants failed
to complete or refused to do the assessment, and as
such, it was excluded from analysis. The FAS verbal pho-
nemic fluency test measured verbal fluency and executive
function. The simple reaction time computerized test
measured attention.
3.1.5. Gait assessment
Participants performed six 10-meter walks at their
comfortable pace, across a 7 meter ! 0.6 meter (length
! width) instrumented walkway (GAITRite, version
4.5; CIR Systems Inc., USA). Sixteen gait characteristics
representing pace, variability, rhythm (i.e., timing charac-
teristics of gait such as step or stance time), asymmetry
(i.e., the absolute difference between left and right steps),
and postural control domains of gait (see Supplementary
Table 1 for definitions) were measured. These were
derived from Lord et al.’s [22] model of gait, developed
in older adults and validated in PD. This model was cho-
sen as a framework to inform selection of gait character-
istics, allow results to be compared with previous work in
PD [23–26], and aid interpretation and communication of
findings.
3.1.6. Data analysis
Data were assessed for normality by inspection of his-
tograms, boxplots, and Shapiro-Wilk tests. Gait variables
that did not fit normal distribution were transformed using
logarithmic or square root transformations. c2 tests were
used to determine differences between groups for sex
and faller status (participants with and without falls dur-
ing the previous year). One-way analysis of variance
and Kruskal-Wallis tests were used to examine differences
between groups for all other variables; Fischer’s Least
Significant Difference post-hoc and Mann Whitney U
tests established where differences lay between dementia
subtypes and controls. Student’s t-test was used to assess
differences in gait characteristics between AD and LBD.
A conservative threshold of P  .01 was applied to ac-
count for multiple comparisons. Stepwise analysis of
covariance assessed group differences for gait outcomes
while controlling for effects of age, height, and sex on
gait outcomes.Effect sizes (eta squared; h2) were calculated for gait
characteristics that distinguished LBD from AD, with h2:
0.01–0.06 5 small, 0.06–0.14 5 medium and
.0.14 5 large [27]. Receiver operating characteristics and
area under the curve (AUC) determined overall accuracy
of selected gait characteristics, with AUC: 0.5 5 test due
to chance, 0.5–0.7 5 low accuracy, 0.7–0.9 5 moderate ac-
curacy, 0.9–1 5 high accuracy, and 1 5 the perfect test
[28,29]. Backward logistic regression identified the
strongest combination of significant gait predictors for
identifying LBD, and AUC was calculated from
probability scores.
Univariate regressions were used to establish significant
relationships between discrete gait impairments with demo-
graphics (age, sex, height), motor disease, and cognition
(standardized MMSE, ACE-III visuospatial subscore,
TMT-A, FAS, Simple Reaction Time task). Significant vari-
ables reported by univariate regressions were placed into the
backward stepwise regression model to identify which fac-
tors made the strongest contribution to gait. Adjusted R2
values were used as explanatory outcomes, demonstrating
the amount of variance the predictors explained of the
dependent gait variable.3.2. Early experimental data—Results
3.2.1. Study participants and demographics
A total of 125 participants were recruited to this study.
Fifteen participants were excluded from this analysis
because of withdrawal from the study (n5 2), clinical diag-
nosis other than AD or LBD (n 5 11), requirement of a
walking stick (n 5 1), and problems processing the data
due to festination (episodic gait interruption) during assess-
ment (n5 1). This left 110 participants (29 controls, 36 AD,
and 45 LBD [30 DLB and 15 PDD]). Participants in the
AD and LBD groups ranged from MCI to moderate demen-
tia, but groups were primarily composed of mild dementia
cases (see Table 1 for all clinical and demographic
information). There were no significant differences for any
gait characteristics between the MCI and dementia groups
within each subtype; therefore, it was deemed feasible to
include both stages of disease in each group (see
Supplementary Table 2).
3.2.2. Differences in gait impairments between AD and LBD
Participants with DLB and PDD had no significant
differences in any gait characteristics (P  .05; see
Fig. 1 and Supplementary Table 2), and the groups were
combined to form a LBD group, increasing statistical
power.
In an adjusted model controlling for age, sex, and
height, people with LBD walked slower (P 5 .016;
h2 5 0.061) with shorter steps (P 5 .011; h2 5 0.066);
greater step (P  .001; h2 5 0.151), swing (P 5 .020;
h2 5 0.057), stance time (P 5 .015; h2 5 0.069), and
step length variability (P  .001; h2 5 0.126); and greater
Table 1
Demographic, clinical, and cognitive information for controls and dementia disease subtypes
s Controls AD LBD F/c2 P
N 29 36 45
MCI/dementia N/A 15/21 20/25 0.003 .570
Age 74 6 9 77 6 6 77 6 6 1.7 .180
Sex (% F) 59D,P 58D,P 16 21 £.001
CDR Scale (0–3) 0 6 0A,D,P 0.8 6 0.3C 0.9 6 0.4 120.7 £.001
Dementia treatment (% Yes) 0A,L 53C 71C 36.9 £.001
Antipsychotics (%Yes) 0 0 0
DAT scan (%Completed) 0L 0L 42.2C,A 33.2 £.001
DAT scan positive/negative N/A N/A 15/4
NART 123 (114–126)A,D,P 117 (101–125) 116 (101–124) 25 £.001
% Faller 19A,D,P 44C 64 14.4 .002
Height (m) 1.67 6 .096 1.66 6 .105 1.69 6 .09 0.8 .500
BMI 26 (21–35) 26 (18–42) 26 (18–43) 2.2 .535
CIRS-G (0–56) 4 (0–11)A,D,P 8 (3–19)C 10 (3–18) 30.7 £.001
UPDRS III 1 (0–11)A,D,P 7 (0–19)C,D,P 31(0–78) 67 £.001
GDS (0–15) 1 (0–5)A,D,P 4 (0–10)C 5 (0–13) 38.2 £.001
ESS (0–24) 4 6 3D,P 6 6 4D,P 10 6 4 14.7 £.001
ABC (0–100) 94 (52–100)A,D,P 89 (37–100)C,P 78 (21–100) 26.9 £.001
BADLS (0–60) 0 (0–1)A,D,P 6 (0–31)C,D 13 (1–31) 55.8 £.001
Cognitive assessments
MMSE (0–30) 30 (25–30)A,L 23 (14–29)C 24 (12–30)C 53.2 £.001
ACE-III Attention (0–18) 18 (17–18)A,L 14 (6–18)C 15 (7–18)C 46.7 £.001
ACE-III Memory (0–26) 25 (19–26)A,L 13 (3–23)C,L 20 (0–26)C,A 54.3 £.001
ACE-III Fluency (0–14) 13 (5–14)A,L 9 (0–13)C 8 (2–13)C 45.2 £.001
ACE-III Language (0–26) 26 (24–26)A,L 23 (11–26)C 24 (0–26)C 37.5 £.001
ACE-III Visuospatial (0–16) 16 (13–16)A,L 14 (6–16)C,L 12 (0–16)C,A 33.1 £.001
ACE-III Total (0–100) 97 (87–100)A,L 74 (29–90)C 77 (15–95)C 59.9 £.001
TMT-A (secs) 31 (19–65)A,L 049 (29–306)C,L 105 (24–955)C,A 47.6 £.001
FAS 48 6 12A,L 35 6 15C,L 28 6 14C,A 18.1 £.001
Simple RT (ms) 373 (291–493)A,L 415 (287–773)C,L 455 (287–3792)C,A 17.9 £.001
NOTE. Data displayed as mean 6 standard deviation were assessed using one-way ANOVAs and Students t-tests, whereas data displayed as median (min-
imum-maximum) were assessed using Kruskal-Wallis and Mann Whitney U tests. Bold values highlight significant differences.
C, different to controls; A, different to AD; D, different to DLB; P, different to PDD; L, different to LBD.
Abbreviations: AD, Alzheimer’s disease; DLB, dementia with Lewy bodies; PDD, LBD, Lewy body dementia; Parkinson’s disease dementia; CDR, Clinical
Dementia Rating; NART, National Adult Reading Test; BMI, body mass index; CIRS-G, Cumulative Illness Rating Scale–Geriatric; UPDRS-III, Unified Par-
kinson’s Disease Rating Scale III; MMSE, Mini–Mental State Examination; ACE-III, Addenbrookes Cognitive Examination III; GDS, Geriatric Depression
Scale; ESS, Epworth Sleepiness Scale; ABC, Activities Balance Confidence Scale; BADLS, Bristol’s Activities of Daily Living; TMT-A, Trail Making Test
Part A; FAS, FAS test; Simple RT, Simple Reaction Time Test Mean Time; ANOVA, analysis of variance.
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(P  .001; h2 5 0.145) compared with AD (see Fig. 1
and Table 2). When considering the more stringent
P  .01, only step time and step length variability, and
step and stance time asymmetry remained significantly
different between groups. Fig. 2 depicts these characteris-
tics in receiver operating characteristics plots.
The AUC was highest for step length variability (AUC:
0.68). All characteristics showed modest accuracy (0.6-
0.7) for distinguishing LBD from AD (see Fig. 2). Backward
logistic regression revealed both step length variability and
step time asymmetry were significant predictors of LBD
with a sensitivity of 73% and specificity of 40%
(AUC 5 0.739; P  .001).
3.2.3. Gait impairments in dementia subtypes compared
with controls
In an adjusted model controlling for age, sex, and height,
both AD and LBD demonstrated with shorter steps; longerstance; and greater stance, step, swing time, step velocity,
and step length variability than controls (P  .01). Partici-
pants with LBD also walked slower, with longer step times;
greater step, swing, and stance time asymmetry; and wider
steps than controls (P  .01).
3.2.4. Explanatory variables of discrete gait impairments in
dementia subtypes
Table 1 reports significant differences between groups
for cognitive assessments. The relationship between gait
variables that significantly differed between disease
groups and normal aging with the cognitive variables
that significantly differed between AD and LBD (mem-
ory, visuospatial, attention, and executive function)
were examined. The relationship between motor disease
severity and discrete gait characteristics was also
assessed.
In AD, greater step velocity variability was significantly
explained by greater global cognitive impairment,
Fig. 1. Radar plots illustrating patterns of gait impairment in disease subtypes. The central black line represents control data, and the lines representing AD,
DLB, and PDD demonstrate howmany standard deviations from zero (z scores based on control means and standard deviations). Abbreviations: SD, variability;
asy, asymmetry; AD, Alzheimer’s disease; DLB, dementia with Lewy bodies; PDD, Parkinson’s disease dementia; LBD, Lewy body dementia. *5 differences
between controls and disease groups, y 5 differences between AD and LBD.
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shorter steps, greater step, and stance time variability were
significantly explained by greater motor disease severity, ac-
counting for 11%–20% of the variance (see Table 3 for sig-
nificant explanatory models, and Supplementary Table 3 for
all univariate regressions).
In LBD, greater step and stance time variability were
significantly explained by greater impairments in verbal
fluency, accounting for 11% of the variance (see Table 4
for significant explanatory models and Supplementary
Table 4 for all univariate regressions). Slower step velocity
was significantly explained by greater motor disease severity
with trends indicating verbal fluency contributed, account-
ing for 17.5% of the variance. Shorter steps were also ex-
plained by greater motor disease severity and shorter
height, accounting for 37.6% of the variance.3.3. Future experiments and validation studies
The objective of this article was to consider if AD and
LBD have unique signatures of gait impairment thatreflect underlying disease pathology. This pilot study pro-
vides initial evidence of discrete pathological signatures
of gait in AD and LBD, and for the differential role of
cognition in gait in each subtype, acting as a proxy for un-
derlying pathology. In addition, it suggested four key
characteristics of gait (step time variability, step length
variability, step time asymmetry, and swing time asymme-
try) could distinguish LBD and AD with modest accuracy
for single characteristics and large effect sizes. This is the
largest study of its kind and the results expand and refine
the findings by Fritz et al. [30], the only other study to
look at AD and LBD. In addition, no significant differ-
ences were found between MCI and dementia groups
within each subtype, contradicting previous literature
[7,31,32]. This reflected the mild nature of participants
with dementia, as they were required to have capacity
to consent and the ability to engage in sustained testing
of .2 hours per session. The finding that people with
MCI had gait impairments that mirrored those with
established dementia supports the use of gait analysis as
an early clinical marker for identification of cognitive
Table 2
Comparison of gait characteristics between controls and dementia disease subtypes
Gait characteristics Controls AD LBD
Unadjusted
model Adjusted model
F P F P
Pace
Step velocity (m/s) 1.26 6 0.19A,L 1.03 6 0.24C 0.95 6 0.24C 16.5 £.001 16 £.001
Step length (m) 0.70 6 0.09A,L 0.57 6 0.11C 0.55 6 0.12C 11.5 £.001 15.9 £.001
Swing SD (ms)ln 14 (7–21)A,L 20 (9–45)C 25 (11–87)C 24.1 £.001 18 £.001
Step time SD (ms)ln 15 (9–23)A,L 21 (9–48)C,L 29 (13–80)C,A 25.1 £.001 20.7 £.001
Stance SD (ms)ln 17 (12–31)A,L 29 (12–69)C 35 (14–118)C 22.5 £.001 19.8 £.001
Variability (SD)
Step velocity SD (m/s)ln 0.052 (0.04–0.11)A,L 0.066 (0.03–0.11)C 0.073 (0.05–0.15)C 12.1 £.001 8.7 £.001
Step length SD (m)ln 0.021 (0.01–0.04)A,L 0.030 (0.01–0.04)C,L 0.035 (0.02–0.08)C,A 32.4 £.001 22.8 £.001
Step width SD (m)ln 0.021 (0.01–0.03) 0.022 (0.01–0.04) 0.022 (0.01–0.05) 0.6 .536 0.2 .812
Rhythm
Step time (ms) 536 6 48L 565 6 57 584 6 70C 5.3 .006 3.9 .024
Swing (ms) 391 6 32 391 6 37 393 6 52 0.04 .961 0.6 .537
Stance (ms)ln 681 (571–787)A,L 722 (615–902)C 777 (599–1029)C 9.2 £.001 7.5 £.001
Asymmetry
Step time asymmetry (ms)sqrt 9 (0.31–43)A,L 12 (0.44–34)C,L 16 (2–65)C,A 4.8 .011 7.8 £.001
Swing asymmetry (ms)sqrt 6 (2–24)A,L 6 (0.34–31)C,L 14 (0.57–44)C,A 4.9 .010 7.3 £.001
Stance asymmetry (ms)sqrt 7 (0.58–24) 8 (0.20–33) 14 (0.13–47) 4.4 .014 4.3 .017
Postural control
Step length asymmetry (m)sqrt 0.018 (0–0.06) 0.019 (0–0.13) 0.02 (0–0.07) 0.3 .741 0.9 .400
Step width (m) .081 6 .023L .099 6 .029 .105 6 .024C 8.1 £.001 6.2 .003
NOTE. Normally distributed data displayed as mean6 standard deviation. Data for transformed variables are displayed as median (minimum-maximum) and
refer to the nontransformed values. Significant values refer to differences between controls, AD, and LBD in the adjusted model controlling for age, sex, and
height. Bold values highlight significant differences.
C, different to controls; A, different to AD; L, different to LBD.
Abbreviations: AD, Alzheimer’s disease; DLB, dementia with Lewy bodies; PDD, LBD, Lewy body dementia; Parkinson’s disease dementia; SD, variability;
ln, log transformed; sqrt, square root transformed.
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predict that characteristics of gait variability and
asymmetry reflect underlying disease pathology and
could be useful for differentiating AD and LBD in early
stages of disease.
A larger replication study with well-defined AD and
LBD groups is required in the future to establish gait as
a proxy marker for underlying neuropathology and there-
fore its potential as a diagnostic tool. This pilot study
included a well-characterized dementia cohort, diagnosed
using relevant criteria and requiring consensus from mul-
tiple clinicians. However, lack of diagnostic certainty is a
limitation for all studies using clinical diagnosis. A defi-
nite diagnosis of dementia subtype can only be ascer-
tained postmortem, and even this can be complicated by
the presence of multiple pathologies such as AD and
LBD. Postmortem follow-up was not within the scope
of this study but will provide valuable insight in future
research. Where information about imaging or recognized
biomarkers were available, they were considered. Howev-
er, this was not possible in all cases and limited our anal-
ysis from considering imaging and biomarkers in
statistical models.
The participants included in each disease groups repre-
sented a spectrum of cognitive impairment. This allowed
greater recruitment within a small catchment area, andonly 4% of participants were considered to have moderate
dementia based on the Clinical Dementia Rating Scale;
leaving 96% with a rating of MCI or mild dementia.
Combining these groups allowed greater power for statis-
tical analysis and was considered appropriate for a pilot
study. In addition, disease-specific MCI criteria were
applied for this study, a newly emerging concept. Previ-
ously, MCI was considered either amnestic or nonamnes-
tic. There is now a movement to define people with MCI
by their LBD symptoms, based on the diagnostic criteria
for DLB [15], along with biomarkers such as positive
dopamine transporter single photon emission computer-
ized tomography imaging techniques, also known as
DAT scans [16]. The criteria has good face validity for
the diagnosis of MCI due to LBD [33]; however, it has
not yet been validated using pathological findings post-
mortem—this is an area of ongoing investigation. Future
studies can address this issue through longitudinal
follow-up assessments—this may give insight into
the utility of gait to predict progression from MCI to de-
mentia.
Another limitation of this study was the absence of in-
formation regarding comorbidities affecting gait, such as
arthritis or presence of cerebrovascular lesions. Owing
to the small sample size, we chose to be conservative in
the variables included in our adjusted models. As such
Table 3
Significant explanatory variables of laboratory-based gait impairment in Alzheimer’s disease
Gait characteristics b SE t P F R R2 Adjust R2 95% CI lower bound 95% CI upper bound
Step velocity
UPDRS-III 20.019 0.000 22.8 .009 7.8 0.436 0.190 0.166 20.031 20.005
Step length (m)
UPDRS-III 20.007 0.003 22.3 .029 5.2 0.369 0.136 0.110 20.013 20.001
Step time SD
UPDRS-III 0.630 0.230 2.7 .010 7.5 0.430 0.185 0.160 0.162 1.098
Stance time SD
UPDRS-III 0.987 0.317 3.1 .004 9.7 0.477 0.228 0.204 0.343 1.631
Step velocity SD
MMSE 20.002 0.001 22.5 .016 6.5 0.400 0.160 0.135 20.003 0.000
Stance time asymmetry
Age 0.598 0.233 2.6 .015 6.6 0.403 0.163 0.138 0.125 1.071
NOTE. Bold values highlight significant differences.
Abbreviations: MMSE, Mini–Mental State Examination; UPDRS-III, Unified Parkinson’s disease rating scale III; SD, variability.
R. Mc Ardle et al. / Alzheimer’s & Dementia 15 (2019) 1367-1377 1373it was not feasible to control for comorbidities or demen-
tia medication, and this may have impacted our results as
they are known covariates of gait and may have improved
or hindered gait performance [4,34–37]. Future studies
require larger age- and gender-matched disease cohorts
to conduct more robust statistical analysis and consider
potential confounders. These cohorts should be character-
ized through recognized biomarkers and followed up at
autopsy to provide clearer results and consider explana-
tory variables of gait impairment. Improved accuracy of
discrete gait characteristics for correctly identifying
LBD from AD may also be found with a better character-
ized cohort.
Although this exploratory study is the largest of its kind to
date, sample sizes were small because of a limited catchment
area; future studies require collaborative multicenter initia-Fig. 2. Receiver operating characteristic plot for gait characteristics that
distinguish disease subtypes. Abbreviations: SD, variability, asy,
asymmetry.tives to recruit sufficiently large cohorts. Power calculations
for sample sizes can be derived from these results, allowing
future research greater generalizability of results and ability
to conduct more complex analysis, such as machine-learning
techniques and validation of gait as a clinical prescreening
tool for differential diagnosis.4. Major challenges for the hypothesis
When considering a discrete pathological signature of
gait in dementia subtypes, we must address major challenges
surrounding limitations in our understanding of age-related
gait impairments, potential mixed pathology in participants,
and the translational potential from research to clinical use.
Slowing of gait in older age is recognized, and the causes
are likely multifactorial [38], such as age-related changes in
physiological, cognitive, and neurological function. There-
fore, it may be difficult to distinguish age-related and
disease-specific gait impairments. This study addressed
this challenge by recruiting older adult controls and control-
ling for age within the comparative analysis. Longitudinal
studies are required to identify gait impairments more spe-
cific to aging than disease; this has been done in PD [39]
but has yet to be considered in comparison to dementia sub-
types.
As addressed in Section 3.3, mixed pathology is an
ongoing challenge with diagnosis of AD and LBD. Within
dementia subtypes, there is also the issue of phenotypes
within the subtypes themselves. For example, posterior
cortical atrophy is an atypical form of AD, which initially
presents with visuospatial impairments [40], whereas those
with logopenic aphasia, a variant of primary progressive
aphasia, experience language difficulties as the core clinical
feature [41]. Both atypical phenotypes are predominately
associated with AD pathology and also demonstrate neuro-
pathological lesions in other neural regions, such as the oc-
cipital and parietal lobe in posterior cortical atrophy and the
left temporoparietal junction area in logopenic aphasia [42].
As it is hypothesized that underlying neuropathology is
Table 4
Significant explanatory variables of laboratory-based gait impairment in Lewy body disease
Gait characteristics b SE t P F R R2 Adjust R2 95% CI lower bound 95% CI upper bound
Step velocity
UPDRS-III 20.005 0.002 22.9 .005 8.7 0.410 0.168 0.149 20.008 20.002
FAS 0.005 0.003 2.1 .040 4.5 0.318 0.101 0.078 0.000 0.011
Total model .009 5.4 0.464 0.215 0.175
FAS 0.004 0.003 1.7 .097 20.001 0.009
UPDRS-III 20.004 0.002 22.4 .022 20.008 20.001
Step length (m)
Sex (male) 0.120 0.045 2.6 .012 7.0 0.373 0.139 0.119 0.028 0.211
Height (m) 0.667 0.169 4.0 .000 15.6 0.516 0.267 0.250 0.327 1.007
UPDRS-III 20.003 0.001 24.2 .000 17.4 0.537 0.288 0.272 20.005 20.002
FAS 0.003 0.001 2.4 .020 5.8 0.357 0.127 0.105 0.000 0.006
Total model .001 13.3 0.637 0.406 0.376
UPDRS-III 20.003 0.001 23.5 .001 20.004 20.001
Height (m) 0.543 0.167 3.3 .002 0.206 0.880
Step time SD
FAS 20.375 0.154 22.4 .019 5.9 0.360 0.129 0.108 20.686 20.064
Stance time SD
FAS 20.533 0.214 22.5 .017 6.2 0.366 0.134 0.113 20.966 20.100
NOTE. Variables that were selected for the backward regression models are detailed under each gait variable. Bold values highlight significant differences.
Abbreviations: FAS, FAS Test; UPDRS-III, Unified Parkinson’s disease rating scale III; SD, variability.
R. Mc Ardle et al. / Alzheimer’s & Dementia 15 (2019) 1367-13771374associated with discrete gait characteristics, it is possible
that different phenotypes will also have their own unique
gait signature. This has yet to be explored in the literature,
but research in the overarching subtypes of AD and LBD
paves the road for narrowing the scope of these studies
even further.
To validate gait as a useful tool for differential diag-
nosis, it should be considered with regard to current vali-
dated biomarkers, such as CSF and imaging biomarkers
[15,17]. It was beyond the scope of this pilot study to
address this; however, we identified discrete gait
impairments between groups despite the potential
influence of mixed pathology. This provides positive
evidence that should this study be replicated in a cohort
with established indirect measures of pathology, such as
imaging, biomarkers, and CSF markers and followed up
to postmortem, true cases of AD and LBD are likely to
have a unique pathological signature of gait. In addition,
the AD and LBD groups presented with the expected
cognitive profiles, supporting the accuracy of clinical
diagnosis and allowing inferences about the role of
underlying pathology in gait, as discussed in Section 5.
Future research should address this challenge by estab-
lishing neural correlates of gait and garnering a better un-
derstanding of the interaction about cognitive and motor
neural pathways in the facilitation of gait.
There is growing interest in the potential of gait analysis
as a diagnostic tool for dementia, with suggestions of instru-
mented walkways being implemented into doctor’s offices
and processed with a risk score algorithm [38]. However,
this plan is limited by the high cost, large space require-
ments, restriction to spatiotemporal gait characteristics,
and length of walk based on the mat’s dimensions [43].
This study used characteristics derived from an instrumentedwalkway to demonstrate unique signatures of gait between
dementia subtypes; however, to translate this research to
clinic, a more user-friendly approach considering other in-
struments for gait analysis along with a cost-effectiveness
analysis is required.
Research in PD is paving theway to validate gait as a clin-
ical biomarker for neurodegeneration [26,39,44–46]. To
consider gait as a potential biomarker for differential
diagnosis of dementia, we must follow the examples set
out in PD research. This suggests we use a validated
model of gait to measure a comprehensive range of
characteristics of gait [47], establish the relationship be-
tween discrete gait and cognitive impairments [12,26] and
markers of pathology [39,45,46,48], and demonstrate the
feasibility of inexpensive tools to measure gait, such as
wearable technology [44].
This work has begun in dementia [4,7,14,49–52];
however, to translate this work for clinical use, we must
move beyond gait speed to consider a range of gait
characteristics, identify progressive gait impairments in
prodromal dementia cohorts, and associate such
progression with the sequence of cognitive and
pathological changes within specific dementia subtypes. In
addition, replication studies using inexpensive tools for
measuring gait, such as wearable technology, are essential
for clinical translation.5. Linkage to major theories
5.1. Associations between discrete gait and cognitive
impairments reflect neuropathological change
Supporting the current theory that discrete gait charac-
teristics are associated with specific cognitive impairments,
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plained greater gait variability in LBD but not AD. Previ-
ous research has also associated gait characteristics
involved in pace, variability, rhythm, and postural control
with cognitive performance in attention, executive func-
tion, information-processing, memory, and visuospatial
abilities—functions mediated by the prefrontal cortex
and associated networks [12,53,54]. These cognitive
abilities are largely regarded as reliant on coordination
of these neural networks to carry out behaviors [55].
The prefrontal cortex has connections with the brainstem,
basal ganglia, limbic system, and thalamus, and integra-
tion of these areas is key to carrying out cognitive func-
tions.
Gait may similarly require coordination of neural net-
works connected to the prefrontal cortex. There is a pro-
posed reciprocal hierarchical relationship between these
structures [55], suggesting that gait engages two distinct
but interacting neural pathways: motor and cognitive
[56,57]. For example, the prefrontal cortex and the
motor cortex require two-way communication to carry
out movements. Should dysfunction arise in either struc-
ture, gait impairment would occur. Pathological changes
in discrete neurodegenerative disorders affect selective
neural pathways during different disease stages. As
such, unique patterns of gait impairment in different dis-
ease subtypes are expected, reflecting the underlying
pathological process.
Pathology impacts associated networks of the prefrontal
cortex early in LBD and later in AD, which may contribute
to differing cognitive presentation, and in turn, the differing
degree of gait impairment for cognitively mediated charac-
teristics, for example, gait variability [58]. Speculatively,
this may suggest that prominent gait impairments occur
early in LBD due to the dysfunction in motor networks,
such as the basal ganglia and associated networks [59,60].
As such, the cognitive network may take greater control of
gait facilitation, transforming gait from an automatic
motor function to a cognitive task. In contrast, AD
pathology occurs in the temporal lobe early in the disease
stages and does not spread to the basal ganglia until later
in the disease [61]. Therefore, cognitive control of gait
may diminish earlier in AD and result in greater reliance
on the motor network to facilitate and modulate gait—hence
why gait impairments are associated with greater motor dis-
ease severity in AD. This may be why the relationship be-
tween gait and prefrontally mediated cognitive functions,
such as executive function, appears more prominently in
LBD than AD.5.2. Gait could act as proxy measure for neuropathology
It is theorized that gait impairments reflect underlying
neurodegenerative pathology. For example, disturbed am-yloid metabolism is implicated in greater impairments in
gait variability as PD progresses [39], whereas cholin-
ergic dysfunction contributes to impairments in pace in
early PD [45]. The finding of greater asymmetry in
LBD supports gait as a surrogate marker for brain func-
tion [62], as this may reflect the asymmetric origins of
pathology in LBD. Asymmetrical neurodegeneration of
the striata has been reported in PD, contributing to the
unilateral onset of motor symptoms [63]. Asymmetrical
uptake of dopamine has been similarly shown in the pos-
terior putamen in PDD [64], and asymmetrical alterations
of the basal ganglia and subcortical areas have been
observed in DLB and PDD [65], supporting our sugges-
tion. To our knowledge, this is the first study investi-
gating gait asymmetry in AD and LBD. This work can
be advanced by considering CSF, imaging, genetics,
and postmortem findings in relation to discrete gait im-
pairments in AD and LBD.6. Conclusions and recommendations
In conclusion, early evidence suggests there are discrete
pathological signatures of gait in very mild AD and LBD,
and that this may be due to the disease-specific role of cogni-
tion in gait. We recommend this research is replicated with
larger well-defined AD and LBD cohorts, taking into ac-
count proxymeasures of pathology such as CSF and imaging
analysis and followed up longitudinally until postmortem.
This will allow greater confidence in findings, as well as
furthering our knowledge of the interactions between
discrete gait characteristics and neural networks. In addition,
we recommend future research follow the framework set out
in PD to describe the trajectory of change in gait during
different disease stages and subtypes and consider the cogni-
tive functions and pathology that underpins disease-specific
signatures of gait.
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1. Systematic review: The authors reviewed the litera-
ture using traditional academic databases (e.g., Sco-
pus), published a structured review of the literature
(Mc Ardle et al., 2016), and updated this search
before this article. All relevant publications have
been appropriately cited.
2. Interpretation: Our findings provide initial evidence
that Alzheimer’s disease and Lewy body disease
have unique signatures of gait impairment, which
reflect profiles of cognitive impairment. This sup-
ports the current theory that gait may act as a proxy
for neuropathology, as gait-cognition relationships
are different between subtypes, and more asymmet-
rical gait in Lewy body disease may reflect more
asymmetrical neurodegeneration.
3. Future direction: This article recommends areas for
future research based on these findings and limita-
tions within this study. Examples include using
well-established biomarkers to improve confidence
in clinical diagnosis for future gait studies and
considering the relationship between discrete gait
characteristics and neuropathology.
References
[1] Kenigsberg PA, Aquino JP, Berard A, Gzil F, Andrieu S, Banerjee S,
et al. Dementia beyond 2025: knowledge and uncertainties. Dementia
(London) 2016;15:6–21.
[2] Bahureksa L, Najafi B, Saleh A, SabbaghM, CoonD,MohlerMJ, et al.
The impact of mild cognitive impairment on gait and balance: a sys-
tematic review andmeta-analysis of studies using instrumented assess-
ment. Gerontology 2017;63:67–83.
[3] Beauchet O, Annweiler C, Callisaya ML, De Cock AM, Helbostad JL,
Kressig RW, et al. Poor gait performance and prediction of dementia:
results from a meta-analysis. J Am Med Dir Assoc 2016;17:482–90.
[4] Wilson J, Allcock L, Mc Ardle R, Taylor JP, Rochester L. The neural
correlates of discrete gait characteristics in ageing: a Structured Re-
view. Neurosci Biobehav Rev 2018;100:344–69.
[5] Yogev-Seligmann G, Hausdorff JM, Giladi N. The role of executive
function and attention in gait. Mov Disord 2008;23:329–42. quiz 472.
[6] Beauchet O, Launay CP, Annweiler C, Allali G. Hippocampal volume,
early cognitive decline and gait variability: which association? Exp
Gerontol 2015;61:98–104.
[7] Mc Ardle R, Morris R, Wilson J, Galna B, Thomas AJ, Rochester L.
What can quantitative gait analysis tell us about dementia and its sub-
types? A structured review. J Alzheimer’s Dis 2017;60:1295–312.
[8] Palmqvist S, Hansson O, Minthon L, Londos E. Practical suggestions
on how to differentiate dementia with Lewy bodies from Alzheimer’s
disease with common cognitive tests. Int J Geriatr Psychiatry 2009;
24:1405–12.
[9] Kane JPM, Surendranathan A, Bentley A, Barker SAH, Taylor JP,
Thomas AJ, et al. Clinical prevalence of Lewy body dementia. Alz-
heimers Res Ther 2018;10:19.[10] Mueller C, Perera G, Rajkumar AP, Bhattarai M, Price A, O’Brien JT,
et al. Hospitalization in people with dementia with Lewy bodies: fre-
quency, duration, and cost implications. Alzheimers Dement (Amst)
2018;10:143–52.
[11] Mueller C, Ballard C, Corbett A, Aarsland D. The prognosis of demen-
tia with Lewy bodies. Lancet Neurol 2017;16:390–8.
[12] Morris R, Lord S, Bunce J, Burn D, Rochester L. Gait and cognition:
mapping the global and discrete relationships in ageing and neurode-
generative disease. Neurosci Biobehav Rev 2016;64:326–45.
[13] Calderon J, Perry RJ, Erzinclioglu SW, Berrios GE, Dening TR,
Hodges JR. Perception, attention, and working memory are dispropor-
tionately impaired in dementia with Lewy bodies compared
with Alzheimer’s disease. J Neurol Neurosurg Psychiatry 2001;
70:157–64.
[14] Allali G, Annweiler C, Blumen HM, Callisaya ML, De Cock AM,
Kressig RW, et al. Gait phenotype from mild cognitive impairment
to moderate dementia: results from the GOOD initiative. Eur J Neurol
2016;23:527–41.
[15] McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor JP,
Weintraub D, et al. Diagnosis and management of dementia with
Lewy bodies: fourth consensus report of the DLB Consortium.
Neurology 2017;89:88–100.
[16] Thomas AJ, Donaghy P, Roberts G, Colloby SJ, Barnett NA,
Petrides G, et al. Diagnostic accuracy of dopaminergic imaging in
prodromal dementia with Lewy bodies. Psychol Med 2019;
49:396–402.
[17] McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR,
Kawas CH, et al. The diagnosis of dementia due to Alzheimer’s dis-
ease: recommendations from the National Institute on Aging-Alz-
heimer’s Association workgroups on diagnostic guidelines for
Alzheimer’s disease. Alzheimer’s Demen 2011;7:263–9.
[18] Emre M, Aarsland D, Brown R, Burn DJ, Duyckaerts C, Mizuno Y,
et al. Clinical diagnostic criteria for dementia associated with Parkin-
son’s disease. Mov Disord 2007;22:1689–707. quiz 837.
[19] King E, O’Brien JT, Donaghy P, Morris C, Barnett N, Olsen K, et al.
Peripheral inflammation in prodromal Alzheimer’s and Lewy body de-
mentias. J Neurol Neurosurg Psychiatry 2018;89:339–45.
[20] Donaghy PC, Taylor JP, O’Brien JT, Barnett N, Olsen K, Colloby SJ,
et al. Neuropsychiatric symptoms and cognitive profile in mild cogni-
tive impairment with Lewy bodies. Psychol Med 2018;48:2384–90.
[21] Movement Disorder Society Task Force on Rating Scales for Parkin-
son’s Disease. The Unified Parkinson’s Disease Rating Scale
(UPDRS): status and recommendations. Mov Disord 2003;18:738.
[22] Lord S, Galna B, Verghese J, Coleman S, Burn D, Rochester L. Inde-
pendent domains of gait in older adults and associated motor and non-
motor attributes: validation of a factor analysis approach. J Gerontol A
Biol Sci Med Sci 2013;68:820–7.
[23] Del Din S, Galna B, Godfrey A, Bekkers EM, Pelosin E, Nieuwhof F,
et al. Analysis of free-living gait in older adults with and without Par-
kinson’s disease and with and without a history of falls: identifying
generic and disease specific characteristics. J Gerontol Ser A
2017:glx254.
[24] Del Din S, Godfrey A, Galna B, Lord S, Rochester L. Free-living gait
characteristics in ageing and Parkinson’s disease: impact of environ-
ment and ambulatory bout length. J Neuroengineering Rehabil 2016;
13:46.
[25] Galna B, Lord S, Burn DJ, Rochester L. Progression of gait dysfunc-
tion in incident Parkinson’s disease: impact of medication and pheno-
type. Mov Disord 2015;30:359–67.
[26] Morris R, Lord S, Lawson RA, Coleman S, Galna B, Duncan GW,
et al. Gait rather than cognition predicts decline in specific cognitive
domains in early Parkinson’s disease. J Gerontol A Biol Sci Med Sci
2017;72:1656–62.
[27] Richardson JTE. Eta squared and partial eta squared as measures of ef-
fect size in educational research. Educ Res Rev 2011;6:135–47.
[28] Akobeng AK. Understanding diagnostic tests 3: receiver operating
characteristic curves. Acta Paediatr 2007;96:644–7.
R. Mc Ardle et al. / Alzheimer’s & Dementia 15 (2019) 1367-1377 1377[29] Greiner M, Pfeiffer D, Smith RD. Principles and practical application
of the receiver-operating characteristic analysis for diagnostic tests.
Prev Vet Med 2000;45:23–41.
[30] Fritz NE, Kegelmeyer DA, Kloos AD, Linder S, Park A, Kataki M,
et al. Motor performance differentiates individuals with Lewy body
dementia, Parkinson’s and Alzheimer’s disease. Gait Posture 2016;
50:1–7.
[31] Choi JS, Oh HS, Kang DW, Mun KR, Choi MH, Lee SJ, et al. Com-
parison of gait and cognitive function among the elderly with Alz-
heimer’s disease, mild cognitive impairment and healthy. Int J PR
Eng MAN-GT 2011;12:169–73.
[32] Maquet D, Lekeu F, Warzee E, Gillain S, Wojtasik V, Salmon E, et al.
Gait analysis in elderly adult patients with mild cognitive impairment
and patients with mild Alzheimer’s disease: simple versus dual task: a
preliminary report. Clin Physiol Funct Imaging 2010;30:51–6.
[33] Donaghy PC, McKeith IG. The clinical characteristics of dementia
with Lewy bodies and a consideration of prodromal diagnosis. Alz-
heimer’s Res Ther 2014;6:46.
[34] Beauchet O, Launay CP, Montero-Odasso M, Annweiler C, Allali G.
Anti-dementia drugs-related changes in gait performance while single
and dual tasking in patients with Alzheimer disease: a meta-analysis.
Curr Alzheimer Res 2015;12:761–71.
[35] Beauchet O, Launay CP, Allali G, Annweiler C. Changes in gait vari-
ability with anti-dementia drugs: a systematic review and meta-anal-
ysis. CNS Drugs 2014;28:513–8.
[36] Henderson EJ, Lord SR, Brodie MA, Gaunt DM, Lawrence AD,
Close JCT, et al. Rivastigmine for gait stability in patients with Parkin-
son’s disease (ReSPonD): a randomised, double-blind, placebo-
controlled, phase 2 trial. Lancet Neurol 2016;15:249–58.
[37] Assal F, Allali G, Kressig RW, Herrmann FR, Beauchet O. Galant-
amine improves gait performance in patients with Alzheimer’s dis-
ease. J Am Geriatr Soc 2008;56:946–7.
[38] Rosano C, Snitz BE. Predicting dementia from decline in gait speed:
are we there yet? J Am Geriatr Soc 2018;66:1659–60.
[39] Rochester L, Galna B, Lord S, Yarnall AJ, Morris R, Duncan G, et al.
Decrease in Ab42 predicts dopa-resistant gait progression in early Par-
kinson disease. Neurology 2017;88:1501–11.
[40] Crutch SJ, Schott JM, Rabinovici GD,MurrayM, Snowden JS, van der
Flier WM, et al. Consensus classification of posterior cortical atrophy.
Alzheimer’s Demen 2017;13:870–84.
[41] Gorno-Tempini ML, Hillis AE, Weintraub S, Kertesz A, Mendez M,
Cappa SF, et al. Classification of primary progressive aphasia and its
variants. Neurology 2011;76:1006–14.
[42] Ghezzi L. Diagnosis of Alzheimer’s disease typical and atypical
forms. In: Galimberti D, Scarpini E, eds. Neurodegenerative Diseases:
Clinical Aspects, Molecular Genetics and Biomarkers. Cham:
Springer International Publishing; 2018. p. 21–8.
[43] Buckley C, Alcock L, McArdle R, Rehman RZU, Del Din S, Mazza C,
et al. The role of movement analysis in diagnosing and monitoring
neurodegenerative conditions: insights from gait and postural control.
Brain Sci 2019;9:34.
[44] Del Din S, Godfrey A, Mazza C, Lord S, Rochester L. Free-living
monitoring of Parkinson’s disease: lessons from the field. Mov Disord
2016;31:1293–313.
[45] Rochester L, Yarnall AJ, Baker MR, David RV, Lord S, Galna B, et al.
Cholinergic dysfunction contributes to gait disturbance in early Par-
kinson’s disease. Brain 2012;135:2779–88.
[46] Gilat M, Bell PT, Ehgoetz Martens KA, Georgiades MJ, Hall JM,
Walton CC, et al. Dopamine depletion impairs gait automaticity byaltering cortico-striatal and cerebellar processing in Parkinson’s dis-
ease. Neuroimage 2017;152:207–20.
[47] Lord S, Galna B, Rochester L. Moving forward on gait measurement:
toward a more refined approach. Mov Disord 2013;28:1534–43.
[48] Yarnall A, Rochester L, Burn DJ. The interplay of cholinergic func-
tion, attention, and falls in Parkinson’s disease. Mov Disord 2011;
26:2496–503.
[49] Mc Ardle R, Morris R, Hickey A, Del Din S, Koychev I, Gunn RN,
et al. Gait in mild Alzheimer’s disease: feasibility of multi-center mea-
surement in the clinic and homewith body-worn sensors: a pilot study.
J Alzheimer’s Dis 2018:1–11.
[50] Beauchet O, Blumen HM, Callisaya ML, De Cock AM, Kressig RW,
Srikanth V, et al. Spatiotemporal gait characteristics associated with
cognitive impairment: a multicenter cross-sectional study, the inter-
continental “Gait, cOgnitiOn & Decline” initiative. Curr Alzheimer
Res 2018;15:273–82.
[51] Annweiler C, Beauchet O, Celle S, Roche F, Annweiler T, Allali G,
et al. Contribution of brain imaging to the understanding of gait disor-
ders in Alzheimer’s disease: a systematic review. Am JAlzheimers Dis
Other Demen 2012;27:371–80.
[52] Verghese J, Robbins M, Holtzer R, Zimmerman M, Wang C, Xue X,
et al. Gait dysfunction in mild cognitive impairment syndromes. J
Am Geriatr Soc 2008;56:1244–51.
[53] Montero-Odasso M, Verghese J, Beauchet O, Hausdorff JM. Gait and
cognition: a complementary approach to understanding brain function
and the risk of falling. J Am Geriatr Soc 2012;60:2127–36.
[54] Verghese J, Wang C, Lipton RB, Holtzer R, Xue X. Quantitative gait
dysfunction and risk of cognitive decline and dementia. J Neurol Neu-
rosurg Psychiatry 2007;78:929–35.
[55] Fuster JM. The prefrontal cortex—an update: time is of the essence.
Neuron 2001;30:319–33.
[56] Leisman G, Moustafa AA, Shafir T. Thinking, walking, talking: inte-
gratory motor and cognitive brain function. Front Public Health 2016;
4:94.
[57] Al-Yahya E, Dawes H, Smith L, Dennis A, Howells K, Cockburn J.
Cognitive motor interference while walking: a systematic review and
meta-analysis. Neurosci Biobehav Rev 2011;35:715–28.
[58] Sheridan PL, Solomont J, Kowall N, Hausdorff JM. Influence of ex-
ecutive function on locomotor function: divided attention increases
gait variability in Alzheimer’s disease. J Am Geriatr Soc 2003;
51:1633–7.
[59] Braak H, Ghebremedhin E, Rub U, Bratzke H, Del Tredici K. Stages in
the development of Parkinson’s disease-related pathology. Cell Tissue
Res 2004;318:121–34.
[60] Middleton FA, Strick PL. Basal ganglia and cerebellar loops: motor
and cognitive circuits. Brain Res Brain Res Rev 2000;31:236–50.
[61] Thal DR, Rub U, Orantes M, Braak H. Phases of a beta-deposition in
the human brain and its relevance for the development of AD.
Neurology 2002;58:1791–800.
[62] Fritz S, Lusardi M. White paper: “walking speed: the sixth vital sign”.
J Geriatr Phys Ther 2009;32:46–9.
[63] Scherfler C, Seppi K, Mair KJ, Donnemiller E, Virgolini I,
Wenning GK, et al. Left hemispheric predominance of nigrostriatal
dysfunction in Parkinson’s disease. Brain 2012;135:3348–54.
[64] Jellinger KA, Korczyn AD. Are dementia with Lewy bodies and Par-
kinson’s disease dementia the same disease? BMC Med 2018;16:34.
[65] Walter U, Dressler D, Wolters A, Wittstock M, Greim B, Benecke R.
Sonographic discrimination of dementia with Lewy bodies and Parkin-
son’s disease with dementia. J Neurol 2006;253:448–54.
